Orphan drugs

#Antisense Oligonucleotides (ASOs) #Orphan drugs #Phase III trial #Rare disease #Ultragenyx

Ultragenyx’s ASO for Angelman Syndrome fails at Phase III

Ultragenyx Pharmaceutical has revealed that its Phase III Aspire study for apazunersen (GTX-102) in Angelman syndrome did not achieve its primary endpoint of change from Baseline in Bayley-4 cognitive raw score.  The trial also failed to achieve the key secondary endpoint of net response in Multidomain Responder… Read More

#News

Radiopharmaceutical drug
#European Medicines Agency #Oncology #Orphan drugs #Perspective Therapeutics #Radiopharmaceuticals

Perspective receives European orphan medicinal product designation

Radiopharmaceuticals company Perspective Therapeutics has received orphan medicinal product designation from the European Commission (EC) for [²¹²Pb]VMT-α-NET for the treatment of gastroenteropancreatic neuroendocrine tumours (GEP-NETs).  The designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).  “Patients with unresectable or metastatic… Read More

#Cancer Research #News #Regulatory

GSK offices
#European Medicines Agency #FDA #GSK #Orphan drugs #Rare disease

JAK inhibitor for VEXAS syndrome gets orphan drug designations

GSK’s momelotinib, a JAK inhibitor with a differentiated mechanism of action, has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome.   VEXAS syndrome is a clonal myeloid disorder with… Read More

#News #Regulatory

FDA headquarters
#FDA #Orphan drugs #Osteosarcoma

FDA grants Orphan Drug Designation to osteosarcoma treatment 

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to a treatment for osteosarcoma.  SOT106, developed by biopharmaceutical company SOTIO Biotech, is a next-generation antibody-drug conjugate (ADC) targeting leucine-rich repeat-containing 15 (LRRC15), a clinically validated target broadly expressed across sarcoma subtypes and in tumour associated stroma.  Preclinical data has shown strong anti-tumour activity… Read More

#News #Regulatory

#Bacteria #Blood cancer #Cancer Research UK #HaemaLogiX #Haematology #Institute of Cancer Research #Myeloma #Neuroscience #NHS #Oncology #Orphan drugs #Parkinson's #Rare diseases #University of Edinburgh

This week in Drug Discovery (16 – 20 March) 

News round-up for 16 – 20 March February by Bruno Quinney, Content Team at DDW.  This week, a pioneering method is being used to make drugs for Parkinson’s disease. Elsewhere, advances have been made in both research and trials for common cancers.  The top stories:    Edinburgh team… Read More

#News

#Drug discovery #Orphan drugs #Rare diseases

Rare disease drugs to generate $400bn by 2032, report reveals 

Rare disease therapies could generate over $400 billion in global sales by 2032, a new report reveals.   Evaluate’s ‘2026 Orphan Drug Report’ predicts the sales of orphan drugs will continue to rise steadily, despite policy changes and pricing turmoil. According to the forecast, orphan drugs will account for over 21% of… Read More

#Business & Investment #News

Gene therapy
#FDA #Gene therapy #Orphan drugs

FDA grants orphan drug designation to MMA treatment 

The US Food and Drug Administration (FDA) has granted orphan drug designation to a treatment for methylmalonic acidaemia (MMA).  GENE202, developed by biotechnology company Genespire, is an in vivo off-the-shelf gene therapy which harnesses the company’s Immune Shielded Lentiviral Vector (ISLV) platform to treat paediatric patients affected by genetic diseases.  GENE02, which has also been granted orphan drug… Read More

#News #Regulatory

FDA
#FDA #Orphan drugs

FDA grants Orphan Drug Designation to gMG treatment CNP-106

The US Food and Drug Administration (FDA) has granted orphan drug designation to CNP-106, an investigational therapy for the treatment of generalised myasthenia gravis (gMG).  CNP-106 is a biodegradable nanoparticle that encapsulates seven acetylcholine receptor (AChR) antigens. It is being evaluated for its potential to induce antigen-specific immune tolerance in… Read More

#News #Regulatory

Neuronal inclusions in Huntington’s disease
#Biotech #Huntington's disease #Orphan drugs

EMA positive towards unique Huntington’s drug

The European Medicines Agency (EMA) Committee for Orphan Medical Products (COMP) has issued a positive opinion for granting orphan drug designation (ODD) to the drug SOM3355 for the treatment of Huntington’s disease.  The decision made by the EMA’s Committee for Orphan Medical Product (COMP) recognises an ongoing… Read More

#News

The European Medicines Agency in Amsterdam
#European Medicines Agency #Graft vs Host Disease #Orphan drugs #ReAlta

Graft-versus-host treatment gets EMA orphan drug designation

The European Medicines Agency (EMA) has granted orphan drug designation to ReAlta’s RLS-0071 (pegtarazimod) for the treatment of graft-versus-host disease (GvHD).  The Orphan Drug Designation was supported by preliminary data from ReAlta’s ongoing Phase II trial, which included data from the initial cohort of steroid-refractory acute GvHD (aGvHD) patients.   The… Read More

#News #Regulatory

Monoclonal antibodies
#FDA #Haematology #Myeloma #Oncology #Orphan drugs #Sanofi

Sanofi’s antibody earns orphan status for multiple myeloma

The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, an IgG1-based Antibody-Dependent Cellular Cytotoxicity-enhanced (ADCC) monoclonal antibody (mAb).  The mAb targets G-protein coupled receptor family C group 5 member D (GPRC5D) for the potential treatment of patients with relapsed or refractory multiple myeloma (R/R MM).  … Read More

#Cancer Research #News #Regulatory

Diffuse large B-cell lymphoma
#Artificial intelligence (AI) #Lantern Pharma #Lymphoma #Oncology #Orphan drugs #Phase I trial

Complete response in heavily pre-treated lymphoma patient

A heavily pretreated patient with aggressive Grade 3 non-germinal centre diffuse large B-cell lymphoma (DLBCL) achieved a complete metabolic response in the ongoing Phase I clinical trial of Lantern Pharma’s LP-284.  Lantern uses an AI approach to determine mechanisms of action of any cancer focused molecule, identify… Read More

#Cancer Research #Editor's Choice #News

Synsapses
#Amyotrophic lateral sclerosis (ALS) #FDA #Neuroscience #Orphan drugs #Spinogenix

First synaptic regenerative therapy for ALS gets orphan status

The European Medicines Agency (EMA) has granted orphan drug designation (ODD) to Spinogenix’s SPG302 for the treatment of people living with amyotrophic lateral sclerosis (ALS).   SPG302 is being developed as the first synaptic regenerative approach for the treatment of ALS, with the potential to restore function in cognition, movement, and… Read More

#Editor's Choice #News #Regulatory

Sickle cells
#FDA #Orphan drugs #Rare disease #Sanofi #Sickle cell disorder (SCD)

Sanofi gets fourth orphan drug designation for rilzabrutinib

The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib for sickle cell disease (SCD).  Rilzabrutinib is an oral, reversible Bruton's tyrosine kinase (BTK) inhibitor that works via multi-immune modulation, to target a reduction in vaso-occlusive crises, which may occur via inflammation.  BTK, expressed in B… Read More

#News #Regulatory

FDA
#Cell therapy #Cytokine Release Syndrome (CRS) #FDA #Orphan drugs #Poolbeg Pharma

Poolbeg granted FDA ODD for CRS cell therapy

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Poolbeg Pharma’s POLB 001 as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome (CRS). The FDA grants orphan status to support the development of medicines for rare disorders affecting less than 200,000… Read More

#News

#European Medicines Agency #Gene therapy #Kidney disease #Orphan drugs #Purespring Therapeutics

EMA orphan designation for IgA nephropathy gene therapy

The European Medicines Agency (EMA) has granted orphan drug designation to Purespring Therapeutics’ PS-002 in IgA nephropathy (IgAN), an autoimmune kidney disease that primarily affects young adults.  Orphan drug designation in the European Union (EU) provides incentives including market exclusivity, protocol assistance (guidance on study design and scientific evaluation) and… Read More

#News #Regulatory